Predict your next investment

Corporation
HEALTHCARE | Biotechnology
ginkgobioworks.com

See what CB Insights has to offer

Total Raised

$796.25M

Investors Count

24

Deal Terms

5

Investments

4

Ginkgo BioWorks Funding, Ginkgo BioWorks Valuation & Ginkgo BioWorks Revenue

15 Fundings

Ginkgo BioWorks's latest funding round was a PIPE for $1,000M on October 19, 2021.

Ginkgo BioWorks's valuation in September 2019 was $4,200M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

10/19/2021

PIPE

$1,000M

$0.00B

((9.99x))

FY 1234

3

9/17/2021

Reverse Merger

$0.00B

((9.99x))

FY 1234

10

7/31/2020

Grant - III

$0.00B

((9.99x))

FY 1234

1

5/28/2020

Series E - II

$99M

$0.00B

((9.99x))

FY 1234

10

9/19/2019

Series E

$99M

$4,200M

$0.00B

((9.99x))

FY 1234

10

Date

10/19/2021

9/17/2021

7/31/2020

5/28/2020

9/19/2019

Round

PIPE

Reverse Merger

Grant - III

Series E - II

Series E

Amount

$1,000M

$99M

$99M

Investors

Valuation

$4,200M

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

3

10

1

10

10

Financials

Income Statement

Income Statement

12/31/2020

12/31/2019

12/31/2018

Total Sales (or Revenue)

$99M

$99M

$99M

Cost of Goods Sold (COGS) including Depreciation and Ammortization

$99M

$99M

$99M

Gross Income

$99M

$99M

$99M

SG&A Excluding Other

$99M

$99M

$99M

Other Operating Expense

$99M

$99M

$99M

EBIT (Operating Income)

$99M

$99M

$99M

Non-Operating Income (Expense)

$99M

$99M

$99M

Interest Expense

$99M

$99M

$99M

Usual Expense

$99M

$99M

$99M

Pretax Income

$99M

$99M

$99M

Income Taxes

$99M

$99M

$99M

Equity in Earnings of Affiliates Income

$99M

$99M

$99M

Other After Tax Adjustments

$99M

$99M

$99M

Consolidated Net Income

$99M

$99M

$99M

Minority Interest Expense

$99M

$99M

$99M

Net Income From Continuing Operations

$99M

$99M

$99M

Preferred Dividends

$99M

$99M

$99M

Net Income Available to Common

$99M

$99M

$99M

EPS (Recurring)

$99M

$99M

$99M

EPS - Basic - Before Extraordinaries

$99M

$99M

$99M

EPS (Diluted)

$99M

$99M

$99M

EBITDA

$99M

$99M

$99M

Stock Option Compensation Expense

$99M

$99M

$99M

Operating Lease Expense

$99M

$99M

$99M

Foreign Currency Adjustment (Net)

$99M

$99M

$99M

Income Statement

Total Sales (or Revenue)

Cost of Goods Sold (COGS) including Depreciation and Ammortization

Gross Income

SG&A Excluding Other

Other Operating Expense

EBIT (Operating Income)

Non-Operating Income (Expense)

Interest Expense

Usual Expense

Pretax Income

Income Taxes

Equity in Earnings of Affiliates Income

Other After Tax Adjustments

Consolidated Net Income

Minority Interest Expense

Net Income From Continuing Operations

Preferred Dividends

Net Income Available to Common

EPS (Recurring)

EPS - Basic - Before Extraordinaries

EPS (Diluted)

EBITDA

Stock Option Compensation Expense

Operating Lease Expense

Foreign Currency Adjustment (Net)

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2018

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Balance Sheet

Balance Sheet

12/31/2020

12/31/2019

12/31/2018

Cash & Short Term Investments

$99M

$99M

$99M

Inventories

$99M

$99M

$99M

Other Current Assets

$99M

$99M

$99M

Total Current Assets

$99M

$99M

$99M

Net Property, Plant & Equipment

$99M

$99M

$99M

Total Investments and Advances

$99M

$99M

$99M

Long-Term Note Receivable

$99M

$99M

$99M

Intangible Assets

$99M

$99M

$99M

Deferred Tax Assets

$99M

$99M

$99M

Other Assets

$99M

$99M

$99M

Total Assets

$99M

$99M

$99M

Short Term Debt (including Current Portion of Long Term Debt)

$99M

$99M

$99M

Accounts Payable

$99M

$99M

$99M

Income Tax Payable

$99M

$99M

$99M

Other Current Liabilities

$99M

$99M

$99M

Total Current Liabilities

$99M

$99M

$99M

Long Term Debt

$99M

$99M

$99M

Provision for Risks Charges

$99M

$99M

$99M

Deferred Tax Liabilities

$99M

$99M

$99M

Other Liabilities

$99M

$99M

$99M

Total Liabilities

$99M

$99M

$99M

Non-Equity Reserves

$99M

$99M

$99M

Preferred Stock - Carrying Value

$99M

$99M

$99M

Common Equity

$99M

$99M

$99M

Total Shareholders Equity

$99M

$99M

$99M

Accumulated Minority Interest

$99M

$99M

$99M

Total Equity

$99M

$99M

$99M

Total Liabilites & Stockholders Equity

$99M

$99M

$99M

Book Value Per Share

$99M

$99M

$99M

Tangible Book Value Per Share

$99M

$99M

$99M

Balance Sheet

Cash & Short Term Investments

Inventories

Other Current Assets

Total Current Assets

Net Property, Plant & Equipment

Total Investments and Advances

Long-Term Note Receivable

Intangible Assets

Deferred Tax Assets

Other Assets

Total Assets

Short Term Debt (including Current Portion of Long Term Debt)

Accounts Payable

Income Tax Payable

Other Current Liabilities

Total Current Liabilities

Long Term Debt

Provision for Risks Charges

Deferred Tax Liabilities

Other Liabilities

Total Liabilities

Non-Equity Reserves

Preferred Stock - Carrying Value

Common Equity

Total Shareholders Equity

Accumulated Minority Interest

Total Equity

Total Liabilites & Stockholders Equity

Book Value Per Share

Tangible Book Value Per Share

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2018

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Cash Flow

Cash Flow

12/31/2020

12/31/2019

12/31/2018

Net Income (Starting Line)

$99M

$99M

$99M

Depreciation

$99M

$99M

$99M

Deferred Taxes & Investment Tax Credit

$99M

$99M

$99M

Other Funds (Non Cash)

$99M

$99M

$99M

Funds from Operations

$99M

$99M

$99M

Extraordinary Item

$99M

$99M

$99M

Changes in Working Capital

$99M

$99M

$99M

Net Operating Cash Flow

$99M

$99M

$99M

Capital Expenditures

$99M

$99M

$99M

Net Assets From Acquisitions

$99M

$99M

$99M

Sale of Fixed Assets and Businesses

$99M

$99M

$99M

Purchase or Sale of Investments

$99M

$99M

$99M

Other Uses

$99M

$99M

$99M

Other Sources

$99M

$99M

$99M

Net Investing Cash Flow

$99M

$99M

$99M

Cash Dividends Paid

$99M

$99M

$99M

Change in Capital Stock

$99M

$99M

$99M

Issuance or Reduction of Debt, Net

$99M

$99M

$99M

Net Financing Active Other Cash Flow

$99M

$99M

$99M

Net Financing Cash Flow

$99M

$99M

$99M

Exchange Rate Effect

$99M

$99M

$99M

Miscellaneous Funds

$99M

$99M

$99M

Net Change in Cash

$99M

$99M

$99M

Free Cash Flow

$99M

$99M

$99M

Cash Flow

Net Income (Starting Line)

Depreciation

Deferred Taxes & Investment Tax Credit

Other Funds (Non Cash)

Funds from Operations

Extraordinary Item

Changes in Working Capital

Net Operating Cash Flow

Capital Expenditures

Net Assets From Acquisitions

Sale of Fixed Assets and Businesses

Purchase or Sale of Investments

Other Uses

Other Sources

Net Investing Cash Flow

Cash Dividends Paid

Change in Capital Stock

Issuance or Reduction of Debt, Net

Net Financing Active Other Cash Flow

Net Financing Cash Flow

Exchange Rate Effect

Miscellaneous Funds

Net Change in Cash

Free Cash Flow

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2018

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Ginkgo BioWorks Deal Terms

5 Deal Terms

Ginkgo BioWorks's deal structure is available for 5 funding rounds, including their Reverse Merger from September 17, 2021.

Round

Reverse Merger

Series E

Series D

Series B

Series A

Funding Date

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

$99M

Post-Money Valuation

$99M

$99M

Amount Raised

$99M

$99M

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Reverse Merger

$99M

$99M

$99M

$99M

$99M

$99M

Series E

$99M

$99M

$99M

$99M

$99M

$99M

Series D

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

Series A

Ginkgo BioWorks Investors

24 Investors

Ginkgo BioWorks has 24 investors. Baillie Gifford & Co. invested in Ginkgo BioWorks's PIPE funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

6/8/2016

10/19/2021

3
Series C, Series E (2019), PIPE (2021)

Asset/Investment Management

United Kingdom

7/23/2015

5/28/2020

6
Series B, Series B - II (2015), Series C (2016), Series D (2017), Series E (2019), Series E - II (2020)

Asset/Investment Management

New York

12/14/2017

5/28/2020

3
Series D, Series E (2019), Series E - II (2020)

Growth Equity

Connecticut

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Incubator/Accelerator

California

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

Illinois

First funding

6/8/2016

7/23/2015

12/14/2017

00/00/0000

00/00/0000

Last Funding

10/19/2021

5/28/2020

5/28/2020

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Rounds

3
Series C, Series E (2019), PIPE (2021)
6
Series B, Series B - II (2015), Series C (2016), Series D (2017), Series E (2019), Series E - II (2020)
3
Series D, Series E (2019), Series E - II (2020)

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Type

Asset/Investment Management

Asset/Investment Management

Growth Equity

Incubator/Accelerator

Venture Capital

Location

United Kingdom

New York

Connecticut

California

Illinois

Ginkgo BioWorks Acquisitions

5 Acquisitions

Ginkgo BioWorks acquired 5 companies. Their latest acquisition was Dutch DNA Biotech on May 17, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/17/2021

$991

Acquired

6

12/16/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/15/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

2/25/2019

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

1/20/2017

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/17/2021

12/16/2020

5/15/2019

2/25/2019

1/20/2017

Investment Stage

Acquired

Acquired

Series A - II

Unattributed

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

Total Funding

$99M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

10

10

10

10

Ginkgo BioWorks Investments

4 Investments

Ginkgo BioWorks has made 4 investments. Their latest investment was in Allonnia as part of their Series A on October 10, 2020.

CBI Logo

Ginkgo BioWorks Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/22/2020

Series A

Allonnia

$40M

Yes

2

6/12/2019

PIPE

Subscribe to see more

$99M

Subscribe to see more

10

10/3/2018

Series B

Subscribe to see more

$99M

Subscribe to see more

10

3/20/2018

Corporate Minority - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/22/2020

6/12/2019

10/3/2018

3/20/2018

Round

Series A

PIPE

Series B

Corporate Minority - II

Company

Allonnia

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$40M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.